Therefore, nanoparticle-based formulations that are being developed and investigated for ischemic stroke therapy are typically composed of three major components, (i) nanoparticle, (ii) thrombolytic agent such as tPA, and/or (iii) imaging agent/cerebrovascular-neuroprotective agent/targeting ligand (Figure 5). Here, PLAT is linked to ischemic stroke.